deltatrials
Completed PHASE1 INTERVENTIONAL 7-arm NCT01656642

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

A Phase Ib, Open-Label Study of The Safety and Pharmacology of Atezolizumab (Anti PD-L1 Antibody) Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With BRAFV600-Mutation Positive Metastatic Melanoma

Sponsor: Genentech, Inc.

Conditions Malignant Melanoma
Interventions Atezolizumab Cobimetinib Vemurafenib
Updated 19 times since 2017 Last updated: Jul 20, 2020 Started: Aug 13, 2012 Primary completion: Mar 25, 2020 Completion: Mar 25, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Malignant Melanoma and is currently completed. Genentech, Inc. leads this study, which shows 19 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Sep 2017 · 4 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Jun 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

▶ Show 14 earlier versions

  1. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Dec 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  3. Oct 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

  5. Apr 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Aug 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

  9. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  11. May 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE1

  12. Mar 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  13. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations